New approaches in oral rotavirus vaccines

References

• Abe M, Ito N, Masatani T, et al. (2011). Whole genome characterization of new bovine rotavirus G21P[29] and G24P[33] strains provides evidence for interspecies transmission. J Gen Virol 92:952–60
   PubMed Web of Science ®Google Scholar
• Anh DD, Carlos CC, Thiem DV, et al. (2011). Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006–2007. Vaccine 29:2029–36
   PubMed Web of Science ®Google Scholar
• Armah GE, Sow SO, Breiman RF, et al. (2010). Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 376:606–14
   PubMed Web of Science ®Google Scholar
• Arvay ML, Curns AT, Terp S, et al. (2009). How much could rotavirus vaccines reduce diarrhea-associated mortality in northern Ghana? A model to assess impact. J Infect Dis 200:S85–91
   Google Scholar
• Barnes GL, Lund JS, Adams L, et al. (1997). Phase I trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. J Pediatr Child Health 33:300–4
   Google Scholar
• Barnes GL, Lund JS, Mitchell SV, et al. (2002). Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine 20:2950–6
   PubMed Web of Science ®Google Scholar
• Bernstein DI. (2006). Live attenuated human rotavirus vaccine, Rotarix™. Semin Pediatr Infect Dis 17:188–94
   PubMedGoogle Scholar
• Bhandari N, Sharma P, Glass RI, et al. (2006). Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomized controlled trial. Vaccine 24:5817–23
   PubMed Web of Science ®Google Scholar
• Bines JE, Patel M, Parashar U. (2009). Assessment of postliscensure safety of rotavirus vaccines, with emphasis on intussusception. J Infect Dis 200:S282–90
   PubMed Web of Science ®Google Scholar
• Bishop RF, Lund J, Cipriani E, et al. (1990). Clinical serological and intestinal immune responses to rotavirus infection of humans. J Med Virol 9:85–110
   Google Scholar
• Blutt SE, Warfield KL, O’Neal CM, et al. (2006). Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine 24:1170–9
   PubMed Web of Science ®Google Scholar
• Carlin JB, Macartney KK, Lee KJ, et al. (2013). Intussusception risk and disease prevention associated with rotavirus vaccines in Australia’s national immunization program. Clin Infect Dis 57:1427–34
   PubMed Web of Science ®Google Scholar
• Casswall TH, Sarker SA, Faruque SM, et al. (2000). Treatment of enterotoxigenic and enteropathogenic Escherichia coli-induced diarrhea in children with bovine immunoglobulin milk concentrate from hyperimmunized cows: a double-blind, placebo-controlled, clinical trial. Scand J Gastroenterol 35:711–18
   PubMed Web of Science ®Google Scholar
• Chackerian B. (2007). Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 6:381–90
   PubMed Web of Science ®Google Scholar
• Chen SC, Jones DH, Fynan EF, et al. (1998). Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 72:5757–61
   PubMed Web of Science ®Google Scholar
• Clark B, McKendrick M. (2004). A review of viral gastroenteritis. Curr Opin Infect Dis 17:461–9
   PubMed Web of Science ®Google Scholar
• Clements-Mann ML, Makhene MK, Mrukowicz J, et al. (1999). Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specifcity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine 17:2715–25
   PubMed Web of Science ®Google Scholar
• Conner ME, Zarley CD, Hu B, et al. (1996). Virus-like particles as a rotavirus subunit vaccine. J Infect Dis 174:S88–92
   PubMed Web of Science ®Google Scholar
• Crawford SE, Labbé M, Cohen J, et al. (1994). Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol 68:5945–52
   PubMed Web of Science ®Google Scholar
• Cross ML. (2002). Microbes versus microbes: immune signals generated by probiotic lactobacilli and their role in protection against microbial pathogens. FEMS Immunol Med Microbiol 34:245–53
   PubMed Web of Science ®Google Scholar
• Danchin M, Kirkwood CD, Lee KJ, et al. (2013). Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine 31:2610–16
   PubMed Web of Science ®Google Scholar
• Das BK, Gentsch JR, Cicirello HG, et al. (1994). Characterization or rotavirus strains from newborns in New Delhi, India. J Clin Microbiol 32:1820–2
   PubMed Web of Science ®Google Scholar
• Davenport V, Groves E, Horton RE, et al. (2008). Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B. J Infect Dis 198:731–40
   PubMed Web of Science ®Google Scholar
• De Marco G, Bracale I, Buccigrossi V, et al. (2009). Rotavirus induces a biphasic enterotoxic and cytotoxic response in human-derived intestinal enterocytes, which is inhibited by human immunoglobulins. J Infect Dis 200:813–19
   PubMed Web of Science ®Google Scholar
• Fischer TK, Viboud C, Parashar U, et al. (2007). Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993–2003. J Infect Dis 195:1117–25
   PubMed Web of Science ®Google Scholar
• Flewett TH, Woode GN. (1978). The rotaviruses – brief review. Arch Virol 57:1–23
   PubMed Web of Science ®Google Scholar
• Global Alliance for Vaccines and Immunizations. (GAVI) Rotavirus vaccine support. Available from: http://www.gavialliance.org/support/nvs/rotavirus/ [last accessed 19 September 2014]
   Google Scholar
• Gentsch J, Das BK, Jiang B, et al. (1993). Similarity of the VP4 protein of human rotavirus strain 116E to that of the bovine B223 strain. Virol 194:424–30
   PubMed Web of Science ®Google Scholar
• Glass RI, Gentsch JR, Ivanoff B. (1996). New lessons for rotavirus vaccines. Science 272:46–8
   PubMed Web of Science ®Google Scholar
• Glass RI, Bresee JS, Turcios R, et al. (2005). Rotavirus vaccines: targeting the developing world. J Infect Dis 192:S160–6
   PubMed Web of Science ®Google Scholar
• Glass RI, Parashar UD, Bresee JS, et al. (2006). Rotavirus vaccines: current prospects and future challenges. Lancet 368:323–32
   PubMed Web of Science ®Google Scholar
• Gray J, Vesikari T, Van Damme P, et al. (2008). Rotavirus. J Pediatr Gastroenterol Nutr 46:S24–31
   PubMed Web of Science ®Google Scholar
• Groome MJ, Moon S, Velasquez D, et al. (2014). Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Organ 92:238–45
   PubMed Web of Science ®Google Scholar
• Haber P, Patel M, Pan Y, et al. (2013). Intussusception after rotavirus vaccines reported to US VAERS, 2006–2012. Pediatrics 131:1042–49
   PubMed Web of Science ®Google Scholar
• Harmsen MM, De Haard HJ. (2007). Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77:13–22
   PubMed Web of Science ®Google Scholar
• Heaton PM, Ciarlet M. (2007). The pentavalent rotavirus vaccine: discovery to licensure and beyond. Clin Infect Dis 45:1618–24
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. (2005). Mucosal immunity and vaccines. Nat Med 11:45–53
   PubMed Web of Science ®Google Scholar
• Justice F, Carlin J, Bines J. (2005). Changing epidemiology of intussusception in Australia. J Paediatr Child Health 41:475–78
   PubMed Web of Science ®Google Scholar
• Kaila M, Isolauri E, Saxelin M, et al. (1995). Viable versus inactivated lactobacillus strain GG in acute rotavirus diarrhea. Arch Dis Child 72:51–3
   PubMed Web of Science ®Google Scholar
• Kirkwood CD. (2010). Genetic and antigenic diversity of human rotaviruses: potential impact on vaccination programs. J Infect Dis 202:S43–8
   PubMed Web of Science ®Google Scholar
• Kodama C, Eguchi M, Sekiya Y, et al. (2005). Evaluation of the Lon-deficient Salmonella strain as an oral vaccine candidate. Microbiol Immunol 49:1035–45
   PubMed Web of Science ®Google Scholar
• Kõll P, Mändar R, Smidt I, et al. (2010). Screening and evaluation of human intestinal lactobacilli for the development of novel gastrointestinal probiotics. Curr Microbiol 61:560–6
   PubMed Web of Science ®Google Scholar
• Lavelle EC, O’Hagan DT. (2006). Delivery systems and adjuvants for oral vaccines. Expert Opin Drug Deliv 3:747–62
   PubMed Web of Science ®Google Scholar
• Lepage P, Vergison A. (2007). Prevention of childhood rotavirus disease through the use of Rotarix™ and Rotateq™ vaccines. Expert Opin Biol Ther 7:1881–92
   PubMed Web of Science ®Google Scholar
• Madhi SA, Cunliffe NA, Steele D, et al. (2010). Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 362:289–98
   PubMed Web of Science ®Google Scholar
• Madhi SA, Kirsten M, Louw C, et al. (2012). Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine 30S:A44–51
   Google Scholar
• Madhi SA, Parashar UD. (2014). 116E rotavirus vaccine development: a successful alliance. Lancet 383(9935):2106--7
   Google Scholar
• Marelli B, Perez AR, Banchio C, et al. (2011). Oral immunization with live Lactococcus lactis expressing rotavirus VP8* subunit induces specific immune response in mice. J Virol Methods 175:28–37
   PubMed Web of Science ®Google Scholar
• Martín MC, Pant N, Ladero V, et al. (2011). Integrative expression system for delivery of antibody fragments by Lactobacilli. Appl Environ Microbiol 77:2174–9
   PubMed Web of Science ®Google Scholar
• Matthijnssens J, Ciarlet M, McDonald SM, et al. (2011). Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol 156:1397–413
   PubMed Web of Science ®Google Scholar
• Matthijnssens J, Otto PH, Ciarlet M, et al. (2012). VP6-sequence-based cutoff values as a criterion for rotavirus species demarcation. Arch Virol 157:1177–82
   PubMed Web of Science ®Google Scholar
• Matthijnssens J, Van Ranst M. (2012). Genotype constellation and evolution of group A rotaviruses infecting humans. Curr Opin Virol 2:426–33
   PubMed Web of Science ®Google Scholar
• Meldrum M. (1998). “A calculated risk”: the Salk polio vaccine field trials of 1954. BMJ 317:1233–6
   PubMed Web of Science ®Google Scholar
• Mullooly J, Drew L, DeStefano F, et al. (1999). Quality of HMO vaccination databases used to monitor childhood vaccine safety. Vaccine Safety DataLink Team. Am J Epidemiol 149:186–94
   PubMed Web of Science ®Google Scholar
• Murphy BR, Morens DM, Simonsen L, et al. (2003). Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 187:1301–8
   PubMed Web of Science ®Google Scholar
• Nayak B, Panda AK, Ray P, Ray AR. (2009). Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination. J Microencapsul 26:154–65
   PubMed Web of Science ®Google Scholar
• Nayak B, Ray AR, Panda AK, Ray P. (2011). Improved immunogenicity of biodegradable polymer particles entrapped rotavirus vaccine. J Biomater Appl 25:469–96
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Jeffery H, Roberts MJ, et al. (1991). Controlled release microparticles for vaccine development. Vaccine 21:67–77
   Google Scholar
• O’Hagan DT, Singh M, Gupta RK. (1998). Poly(lactide-co-glycolide) microparticles for the development of single dose controlled release vaccines. Adv Drug Deliv Rev 32:225–46
   PubMed Web of Science ®Google Scholar
• O’Ryan M. (2007). Rotarix™ (RIX4414): an oral human rotavirus vaccine. Expert Rev Vacc 6:11–19
   PubMed Web of Science ®Google Scholar
• O’Ryan M, Linhares AC. (2009). Update on Rotarix™: an oral human rotavirus vaccine. Expert Rev Vaccines 8:1627–41
   PubMed Web of Science ®Google Scholar
• Pant N, Hultberg A, Zhao Y, et al. (2006). Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis 154:1580–8
   Google Scholar
• Pant N, Marcotte H, Brüssow H, et al. (2007). Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. BMC Microbiol 7:86–91
   PubMedGoogle Scholar
• Pant N, Marcotte H, Hermans P, et al. (2011). Lactobacilli producing bispecific llama-derived anti-rotavirus proteins in vivo for rotavirus-induced diarrhea. Future Microbiol 6:583–93
   PubMed Web of Science ®Google Scholar
• Parashar UD, Bresse JS, Gentsch JR, Glass RI. (1998). Rotavirus. Emerg Infect Dis 4:561–70
   PubMed Web of Science ®Google Scholar
• Parashar UD, Gibson CJ, Bresse JS, Glass RI. (2006). Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12:304–6
   PubMed Web of Science ®Google Scholar
• Patel MM, López-Collada VR, Bulhões MM, et al. (2011). Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 364:2283–92
   PubMed Web of Science ®Google Scholar
• Programme for Control of Diarrhoeal Diseases. (1988). Sixth Programme Report, 1986–1987. WHO/CCD/88.28. pp. 56–51
   Google Scholar
• Prymula R, Kriz P, Kaliskova E, et al. (2009). Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine 28:71–8
   PubMed Web of Science ®Google Scholar
• Qiao X, Li G, Wang X, et al. (2009). Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice. BMC Microbiol 9:249
   PubMedGoogle Scholar
• Raghuvanshi RS, Singh OM, Panda AK. (2001). Formulation and characterization of immunoreactive tetanus toxoid biodegradable polymer particles. Drug Deliv 2:99–106
   Google Scholar
• Ridgway D, Wolff LJ. (1993). Active immunization of children with leukemia and other malignancies. Leuk Lymphoma 9:177–92
   PubMed Web of Science ®Google Scholar
• Rippinger CM, Patton JT, McDonald SM. (2010). Complete genome sequence analysis of candidate human rotavirus vaccine strains RV3 and 116E. Virology 405:201–13
   PubMed Web of Science ®Google Scholar
• Roukens AH, Vossen AC, Bredenbeek PJ, et al. (2008). Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One 3:e1993
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. (2006). Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New Engl J Med 354:11–22
   PubMed Web of Science ®Google Scholar
• Seegers JFML. (2002). Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol 20:508–15
   PubMed Web of Science ®Google Scholar
• Shaobing Z, Xianmo D, Xiaohong L, et al. (2004). Synthesis and characterization of biodegradable low molecular weight aliphatic polyesters and their use in protein-delivery systems. J Appl Polym Sci 91:1848–56
   Web of Science ®Google Scholar
• Soenarto Y, Aman AT, Bakri A, et al. (2009). Burden of severe rotavirus diarrhea in Indonesia. J Infect Dis 200:S188–94
   PubMedGoogle Scholar
• Steele AD, Patel M, Cunliffe NA, et al. (2012). Workshop on intussusception in African countries – meeting report. Vaccine 30:A185–9
   Google Scholar
• Stijlemans B, Conrath K, Cortez-Retamozo V, et al. (2004). Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 279:1256–61
   PubMed Web of Science ®Google Scholar
• Sturesson C, Artursson P, Ghaderi R, et al. (1999). Encapsulation of rotavirus into poly(lactide-co-glycolide) microspheres. J Control Rel 59:377–89
   PubMed Web of Science ®Google Scholar
• Tacket CO, Sztein MB, Losonsky GA, et al. (2003). Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 108:241–7
   PubMed Web of Science ®Google Scholar
• Tang D, Devit M, Johnston SA. (1992). Genetic immunization is a simple method for eliciting an immune response. Nature 356:152–54
   PubMed Web of Science ®Google Scholar
• Tate JE, Patel MM, Steele AD, et al. (2010). Global impact of rotavirus vaccines. Expert Rev Vaccines 9:395–407
   PubMed Web of Science ®Google Scholar
• Tate JE, Burton AH, Boschi-Pinto C, et al. (2012). 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 12:136–41
   PubMed Web of Science ®Google Scholar
• Tu HA, Woerdenbag HJ, Kane S, et al. (2011). Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vacc 10:1037–51
   PubMed Web of Science ®Google Scholar
• Uren TK, Wijburg OLC, Simmons C, et al. (2005). Vaccine-induced protection against gastrointestinal bacterial infections in the absence of secretory antibodies. Eur J Immunol 35:180–8
   PubMed Web of Science ®Google Scholar
• van der Vaart JM, Pant N, Wolvers D, et al. (2006). Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine 24:4130–7
   PubMed Web of Science ®Google Scholar
• Velásquez FR, Colíndres RE, Grajales C, et al. (2012). Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 31:736–44
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, et al. (2006a). Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New Engl J Med 354:23–33
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen AV, Majuri J, et al. (2006b). Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and Rhesus–Rhesus-Human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis 194:370–6
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Bouckenooghe A, et al. (2011). Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine 29:2079–84
   PubMed Web of Science ®Google Scholar
• Ward RL, Bernstein DI. (2009). Rotarix: a rotavirus vaccine for the world. Clin Infect Dis 48:222–8
   PubMed Web of Science ®Google Scholar
• Ward RL, McNeal MM, Steele AD. (2008). Why does the world need another rotavirus vaccine? Ther Clin Risk Manag 4:49–63
   PubMedGoogle Scholar
• Weintraub ES, Baggs J, Duffy J, et al. (2014). Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med 370:513–19
   PubMed Web of Science ®Google Scholar
• Wen K, Li G, Bui T, et al. (2012). High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs. Vaccine 30:1198–207
   PubMed Web of Science ®Google Scholar
• Xiang SD, Selomuly AC, Ho J, et al. (2010). Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:205–18
   PubMed Web of Science ®Google Scholar
• Yih WK, Lieu TA, Kulldorff M, et al. (2014). Intussuception Risk after Rotavirus Vaccination in U.S. Infants. N Eng J Med 370:503–12
   PubMed Web of Science ®Google Scholar
• Zaman K, Sack DA, Yunus M, et al. (2009). Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 27:1333–9
   PubMed Web of Science ®Google Scholar
• Zhang W, Azevedo MSP, Wen K, et al. (2008). Probiotic Lactobacillus acidophilus enhances the immunogenicity of an oral rotavirus vaccine in gnotobiotic pigs. Vaccine 26:3655–61
   PubMed Web of Science ®Google Scholar
• Zhou H, Guo L, Wang M, et al. (2011). Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expression VP6 induces protective immunization against rotavirus in mice. Virol J 8:3–11
   PubMed Web of Science ®Google Scholar